CA2944330A1 - Composition pharmaceutique liquide d'adalimumab - Google Patents
Composition pharmaceutique liquide d'adalimumab Download PDFInfo
- Publication number
- CA2944330A1 CA2944330A1 CA2944330A CA2944330A CA2944330A1 CA 2944330 A1 CA2944330 A1 CA 2944330A1 CA 2944330 A CA2944330 A CA 2944330A CA 2944330 A CA2944330 A CA 2944330A CA 2944330 A1 CA2944330 A1 CA 2944330A1
- Authority
- CA
- Canada
- Prior art keywords
- formulation
- adalimumab
- buffer
- pharmaceutical composition
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention concerne une composition pharmaceutique liquide comprenant un anticorps anti-TNFa, un tampon, un agent stabilisant et un agent tensio-actif.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN1248/MUM/2014 | 2014-04-02 | ||
PCT/IN2015/000092 WO2015151115A1 (fr) | 2014-04-02 | 2015-02-18 | Composition pharmaceutique liquide d'adalimumab |
IN1248MU2014 IN2014MU01248A (fr) | 2014-04-02 | 2015-02-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2944330A1 true CA2944330A1 (fr) | 2015-10-08 |
Family
ID=54239505
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2944330A Abandoned CA2944330A1 (fr) | 2014-04-02 | 2015-02-18 | Composition pharmaceutique liquide d'adalimumab |
Country Status (5)
Country | Link |
---|---|
US (2) | US10688187B2 (fr) |
EP (1) | EP3125928A4 (fr) |
CA (1) | CA2944330A1 (fr) |
IN (1) | IN2014MU01248A (fr) |
WO (1) | WO2015151115A1 (fr) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2572919T3 (es) | 2014-05-23 | 2016-06-03 | Ares Trading S.A. | Composición farmacéutica líquida |
ES2607489T3 (es) | 2014-05-23 | 2017-03-31 | Ares Trading S.A. | Composición farmacéutica líquida |
EP2946765B1 (fr) * | 2014-05-23 | 2016-08-31 | Ares Trading S.A. | Composition pharmaceutique liquide |
AU2017287743C1 (en) * | 2016-06-30 | 2020-10-01 | Celltrion Inc. | Stable liquid pharmaceutical preparation |
JP7177777B2 (ja) * | 2017-01-11 | 2022-11-24 | セルトリオン, インク. | 安定した液体製剤 |
MX2019010895A (es) * | 2017-03-16 | 2019-11-05 | Lg Chemical Ltd | Formulacion liquida de anticuerpo anti-tnf alfa. |
AU2020225202B2 (en) | 2019-02-18 | 2023-10-26 | Eli Lilly And Company | Therapeutic antibody formulation |
EP4037703A4 (fr) * | 2019-10-02 | 2023-12-06 | Alamab Therapeutics, Inc. | Formulations d'anticorps anti-connexine |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5580856A (en) | 1994-07-15 | 1996-12-03 | Prestrelski; Steven J. | Formulation of a reconstituted protein, and method and kit for the production thereof |
HU228630B1 (en) | 1996-02-09 | 2013-04-29 | Abbott Biotech Ltd | Use of human anti bodies that bind human tnf-alpha and process for inhibiting of human tnf-alpha activity |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
ES2477996T3 (es) | 2000-08-11 | 2014-07-18 | Chugai Seiyaku Kabushiki Kaisha | Preparaciones estabilizadas que contienen un anticuerpo |
WO2003072060A2 (fr) * | 2002-02-27 | 2003-09-04 | Immunex Corporation | Preparation de polypeptides |
US20040033228A1 (en) | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
NZ602498A (en) * | 2007-11-30 | 2014-08-29 | Abbvie Inc | Protein formulations and methods of making same |
TWI603739B (zh) * | 2010-11-11 | 2017-11-01 | 艾伯維生物技術有限責任公司 | 具有增進高濃度之抗-TNFα抗體之液體調配物 |
MX352823B (es) * | 2011-10-28 | 2017-12-04 | Integritybio Inc | Formulaciones de proteinas que contienen aminoacidos. |
NZ629261A (en) * | 2012-03-07 | 2017-08-25 | Cadila Healthcare Ltd | Pharmaceutical formulations of tnf-alpha antibodies |
FR2994390B1 (fr) | 2012-08-10 | 2014-08-15 | Adocia | Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee |
KR102238677B1 (ko) * | 2012-09-07 | 2021-04-12 | 코히러스 바이오사이언시즈, 인코포레이티드 | 아달리무맙의 안정한 수성 제형 |
EP2946765B1 (fr) | 2014-05-23 | 2016-08-31 | Ares Trading S.A. | Composition pharmaceutique liquide |
TW201636047A (zh) | 2015-01-28 | 2016-10-16 | 麥博賽恩斯有限公司 | 抗-TNF-α抗體之醫藥調配物 |
-
2015
- 2015-02-18 CA CA2944330A patent/CA2944330A1/fr not_active Abandoned
- 2015-02-18 WO PCT/IN2015/000092 patent/WO2015151115A1/fr active Application Filing
- 2015-02-18 EP EP15774333.7A patent/EP3125928A4/fr not_active Withdrawn
- 2015-02-18 IN IN1248MU2014 patent/IN2014MU01248A/en unknown
- 2015-02-18 US US15/301,421 patent/US10688187B2/en active Active
-
2020
- 2020-06-05 US US16/894,196 patent/US20200405864A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP3125928A1 (fr) | 2017-02-08 |
IN2014MU01248A (fr) | 2015-10-09 |
US10688187B2 (en) | 2020-06-23 |
US20170106090A1 (en) | 2017-04-20 |
US20200405864A1 (en) | 2020-12-31 |
EP3125928A4 (fr) | 2017-11-29 |
WO2015151115A1 (fr) | 2015-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200405864A1 (en) | Liquid pharmaceutical composition of adalimumab | |
AU2013255413C1 (en) | Pharmaceutical formulations of TNF-alpha antibodies | |
TWI548424B (zh) | 依那西普之安定的液體調配劑 | |
EP2568960B1 (fr) | PRÉPARATION LIQUIDE DE POLYPEPTIDES CONTENANT UN DOMAINE Fc D'UNE IMMUNOGLOBULINE | |
CN106061468B (zh) | 包含TNFR和Fc区的融合蛋白的液体制剂 | |
TWI409082B (zh) | 用於長效型粒細胞集落刺激因子(g-csf)共軛物之液態劑型 | |
JP2023018090A (ja) | 高濃度のタンパク質ベース治療薬を含有する医薬組成物における安定化化合物としてのアミノ酸の使用 | |
US11173208B2 (en) | Liquid formulation comprising GM-CSF neutralizing compound | |
KR102106914B1 (ko) | Gm-csf를 중화하는 화합물을 포함하는 액체 제제 | |
JP6339578B2 (ja) | Gm−csf中和化合物を含む凍結乾燥製剤 | |
JP2018535242A (ja) | 高濃度のタンパク質ベースの治療剤を含有する医薬組成物中の非晶質安定化化合物としてのアミノ酸と糖との最適比 | |
US10918698B2 (en) | Lyophilized pharmaceutical composition of Fc-peptide fusion protein | |
AU2021250949A1 (en) | Liquid Pharmaceutical Composition | |
JPWO2008029908A1 (ja) | 抗体を含有する安定な凍結乾燥医薬製剤 | |
WO2018124948A1 (fr) | Composition pharmaceutique aqueuse d'un anticorps monoclonal recombinant pour le facteur de nécrose tumorale (tnf) α | |
RU2665966C2 (ru) | Водная фармацевтическая композиция рекомбинантного моноклонального антитела к ФНОα | |
CN104740609A (zh) | 一种受体抗体融合蛋白的药物组合物 | |
RU2764521C2 (ru) | Водная фармацевтическая композиция рекомбинантного моноклонального антитела к ФНОа | |
JP2022551622A (ja) | インテグリン抗体の安定な製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20191129 |
|
FZDE | Discontinued |
Effective date: 20220208 |